MedTrace Logo

Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent

NCT03952273 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3141

Last updated 2023-04-26

No results posted yet for this study

Summary

SORT OUT XI Comparison of Combo™ stent and BioMatrix Alpha™ stent in the treatment of unselected patients with ischemic heart disease.

Conditions

Interventions

COMBINATION_PRODUCT

PCI with BioMatrix Alpha™ stent

Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent

COMBINATION_PRODUCT

PCI with Combo™ stent

Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • OrbusNeich

    collaborator INDUSTRY

  • Biosensors International

    collaborator OTHER

  • Phillip Freeman

    lead OTHER

Principal Investigators

  • Phillip Freemann, MD · Aalborg University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-14
Primary Completion
2023-03-19
Completion
2030-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03952273 on ClinicalTrials.gov